Citigroup
PTX

Citigroup’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Citigroup’s Portfolio PTX Stock Details PTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-3,672
Closed -$38K – 7764
2016
Q1 		$38K Buy
3,672
+2,349
+178% +$46.7K ﹤0.01% 6256
2015
Q4 		$39K Buy
1,323
+914
+223% +$27.6K ﹤0.01% 6115
2015
Q3 		$12K Sell
409
-861
-68% -$41.2K ﹤0.01% 6356
2015
Q2 		$75K Buy
1,270
+576
+83% +$40.6K ﹤0.01% 5231
2015
Q1 		$74K Sell
694
-688
-50% -$65.6K ﹤0.01% 5255
2014
Q4 		$130K Buy
1,382
+1,256
+997% +$120K ﹤0.01% 5033
2014
Q3 		$10K Buy
126
+57
+83% +$4.49K ﹤0.01% 6295
2014
Q2 		$6K Sell
69
-209
-75% -$12.8K ﹤0.01% 6417
2014
Q1 		$15K Sell
278
-461
-62% -$15.2K ﹤0.01% 6188
2013
Q4 		$19K Buy
739
+268
+57% +$6.38K ﹤0.01% 6203
2013
Q3 		$13K Sell
471
-477
-50% -$15.3K ﹤0.01% 6122
2013
Q2 		$35K Buy
+948
New +$35.5K ﹤0.01% 5580

Other funds holding PTX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Citigroup's PTX Position: Q2 2016 in Review

Citigroup sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q2 2016, closing a stake of 3,672 shares — an estimated $38K sold.

Citigroup first reported a position in PTX in Q2 2013 and held it in 12 quarters. The position peaked at $130K in Q4 2014. 56 funds tracked by Wall St. Rank hold PTX as of Q2 2016.

  • Citigroup reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q2 2016 after selling out during the quarter.
  • Citigroup sold 3,672 Pernix Therapeutics Holdings, Inc. shares in Q2 2016, an estimated $38K.
  • Citigroup first reported a position in Pernix Therapeutics Holdings, Inc. in Q2 2013 and held it in 12 quarters.
  • Citigroup's Pernix Therapeutics Holdings, Inc. position peaked at $130K in Q4 2014.
  • 56 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q2 2016.

Based on Citigroup's 13F filing for Q2 2016, filed 12 Aug 2016.